CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Cue Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$16.08−0.63 (-3.77%)
Close on Oct 19, 2026
- Market cap
- $101.96M
- P/E (TTM)
- –
- Dividend yield
- –
Cue Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Market Cap | $116.81M | $164.85M |
| Enterprise Value | $99.42M | $87.06M |
| PS Ratio | 3.10 | 3.60 |
| PB Ratio | 50.57 | 2.03 |
| P/TBV Ratio | 50.57 | 2.31 |
Enterprise value
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| EV / Sales | 2.64 | 2.43 |
Income (trailing twelve months)
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Revenue | $37.65M | $57.94M |
| Operating Income | -$98.67M | -$21.44M |
| Net Income | -$164.11M | -$22.46M |
| EBITDA | -$97.31M | -$16.91M |
| EPS (Diluted) | -$26.88 | -$0.83 |
Margins
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Operating Margin | -262.0% | -44.5% |
| Profit Margin | -435.8% | -39.2% |
| EBITDA Margin | -258.4% | -31.3% |
| FCF Margin | -133.2% | -8.85% |
Returns
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -1603.5% | -53.1% |
| Return on Assets (ROA) | -459.6% | -41.0% |
| Return on Capital Employed (ROCE) | -1039.8% | -37.8% |
Growth
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 354.4% | 6.01% |
| Revenue Growth (3Y CAGR) | 180.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 54.2% | 6.42% |
Balance sheet
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $17.39M | $62.42M |
| Net Cash (Debt) | $17.39M | $15.68M |
| Net Cash Per Share | $2.39 | $0.66 |
| Equity (Book Value) | $2.31M | $48.79M |
| Book Value Per Share | $0.32 | $1.36 |
| Tangible Book Value | $2.31M | $23.06M |
| Working Capital | $5.41M | $75.77M |
Financial position
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Current Ratio | 1.25 | 3.30 |
| Quick Ratio | 1.07 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$50.05M | -$12.35M |
| Capital Expenditures | -$121.00K | -$1.06M |
| Free Cash Flow | -$50.17M | -$20.28M |
| FCF Per Share | -$6.91 | -$0.42 |
Efficiency
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 1.05 | 0.38 |
| Revenue Per Employee | $1.30M | $398.96K |
| Profits Per Employee | -$5.66M | -$703.34K |
| Employee Count | 29 | 74 |
Dividends and yields
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -140.5% | -22.7% |
| FCF Yield | -42.9% | -9.07% |
Shares
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 7,264,410 | 58,179,650 |
| Shares Change (YoY) | 84.0% | 11.1% |
| Shares Change (QoQ) | 60.6% | 0.54% |
| Float | 5,972,500 | 49,173,100 |
| Shares Held by Insiders | 17.8% | 11.6% |
| Shares Held by Institutions | 22.6% | 59.4% |
Scores
| Measure | Cue Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -30.71 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Cue Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.